Liposomal Formulation of Bevasizuamb for Intravitreal Administration: Increased Half-Life, Decreased Side Effects

Intravitreal injection is the common method for treatment of the posterior segment eye diseases. The advantage of intravitreal injection is achieving the desired concentration of drug inside the eye and reduction of drug side effects. Unfortunately, repeated intravitreal injections can cause several ocular complications including; vitreous hemorrhage, endophthalmitis, retinal detachment and cataract. For this reason, it seems the usage of sustained release drug delivery systems is helpful. Bevacizumab (Avastin ), antivascular endothelial growth factor (VEGF) monoclonal antibody, is used for the treatment of different ocular diseases such as neovascular age-related macular degeneration, neovascular glaucoma, diabetic retinopathy, retinal vein occlusions, etc. For reduction of drug side effects and improvement of drug half-life after intravitreal administration, we suggest preparation of liposomal bevacizumab as novel drug delivery system and comparison of this new formulation with conventional formulation in the market.